Skip to main content

Table 1 The association of prostate cancer clinicopathological features and HRD scores in total, localized, and metastatic cohorts

From: Homologous recombination deficiency (HRD) score in aggressive prostatic adenocarcinoma with or without intraductal carcinoma of the prostate (IDC-P)

  

HRD as continuous variable

HRD as dichotomous variable

Mean (std)

Median (IQR)

P value1

HRD score≥21

P value2

HRD score≥30

P Value3

Total cohort

Total ( n =123)

20.81 (12.83)

21.00 (11.00, 29.00)

 

65 (52.9%)

 

30 (24.3%)

 

IDC-P

 IDC-P (+), N =77

23.00 (12.11)

23.00 (14.00, 30.00)

0.002

47 (61.0%)

0.019

23 (29.8%)

0.107

 IDC-P (-), N =46

16.52 (12.98)

14.00 (5.75, 25.00)

 

18 (39.1%)

 

7 (15.2%)

 

IDC-P pattern

 Pattern 1, N =19

20.21 (9.60)

21.00 (13.00, 28.00)

0.005*

11 (57.9%)

0.059*

3 (15.7%)

0.048*

 Pattern 2, N =58

24.41 (12.73)

24.00 (14.00, 32.75)

 

36 (62.1%)

 

20 (34.4%)

 

Metastasis

 Localized, N =45

16.33 (12.92)

13.00 (4.50, 28.00)

0.008

19 (42.2%)

0.073

7 (15.5%)

0.130

 mPCa, N =78

23.40 (12.12)

22.00 (14.75, 30.50)

 

46 (59.0%)

 

23 (29.4%)

 

ISUP grade

 Grades 1–3, N =16

11.50 (8.73)

10.00 (5.50, 20.25)

0.001

4 (25.0%)

0.013

0

0.015

 Grades 4–5, N =103

22.73 (12.40)

23.00 (13.50, 30.00)

 

60 (58.3%)

 

29 (28.2%)

 

 NA, N =4

8.75 (17.5)

0

 

1 (25%)

 

1 (25%)

 

Localized cohort

IDC-P

 IDC-P (+), N =27

20.04 (12.34)

23.00 (11.00, 28.00)

0.017

15 (55.6%)

0.027

5 (18.5%)

0.801

 IDC-P (-), N =18

10.78 (12.03)

6.50 (2.50, 14.50)

 

4 (22.2%)

 

2 (11.1%)

 

IDC-P pattern

 Pattern 1, N =8

15.50 (10.98)

13.50 (6.50, 27.50)

0.038*

3 (37.5%)

0.040*

0

0.181*

 Pattern 2, N =19

21.95 (12.65)

24.00 (13.00, 30.00)

 

12 (63.2%)

 

5 (26.3%)

 

Metastatic cohort

IDC-P

 IDC-P (+), N =50

25.18 (11.71)

23.00 (18.75, 32.00)

0.065

32 (64.0%)

0.228

18 (36.0%)

0.154

 IDC-P (-), N =28

20.21 (12.40)

20.00 (12.25, 25.75)

 

14 (50.0%)

 

5 (17.8%)

 

IDC-P pattern

 Pattern 1, N =11

21.83 (11.70)

20.50 (13.75, 30.00)

0.173*

8 (72.7%)

0.387*

3 (27.3%)

0.187*

 Pattern 2, N =39

27.06 (11.47)

25.50 (20.00, 35.75)

 

24 (61.6%)

 

15 (38.5%)

 
  1. P value1: Comparing HRD score as continuous variables (Rank-sum test); P value2: comparing HRD score ≥21 vs. <21 (chi-square test); P value3: comparing HRD score ≥30 vs. <30 (chi-square test)
  2. HRD homologous recombination deficiency, IDC-P intraductal carcinoma of the prostate, mPCa metastatic prostate cancer, std standard deviation, IQR interquartile range
  3. *IDC-P (-) vs. IDC-P pattern 1 vs. IDC-P pattern 2
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us